Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...
In this article, we will look at the 11 Best Undervalued Stocks to Invest in Now.
Let's continue. An additional factor that, in my opinion, makes Novartis an attractive stock for long-term investors is its acquisition of Anthos Therapeutics for up to $3.1 billion. I believe ...
Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal For over 30 years, Congress has imposed price ceilings on prescription drugs ...
Spotlight Therapeutics, a startup with a bold vision for delivering CRISPR therapies into the body without the need for viral vectors or lipid nanoparticles, has … ...
“In some patients, physicians and patients find themselves in a difficult situation when a patient is at risk of having a stroke and the patient is at high risk for bleeding,” said Dan Bloomfield, ...
Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the comp ...
Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions, for an up front payment of $925 million. Anthos was founded in 2019 by Novartis and the private equity ...
The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback